At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 373 enrolled
Drug / intervention
DSXS +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS 1535 in Patients With Mild to Severe Scalp Psoriasis
In Brief
A Phase 3 clinical trial evaluating DSXS and Placebo for Scalp Psoriasis. Completed, enrolled 373 participants.
Detailed Summary
A Randomized Double-Blind, Vehicle-Controlled, Parallel Design, Multiple-Site, Phase III Clinical Study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScalp Psoriasis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedOct 2016
Primary CompletionDec 2016
Study CompletionSep 2017
TodayJul 2026
First PostedOct 13, 2016
Enrollment StartMar 1, 2016
Primary CompletionDec 1, 2016
Study CompletionSep 29, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.7 years ago
Interventions
DSXSdrug
topical product
Placebodrug
topical product